drugset / Trial / NCT01519284

Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic

NCT01519284 ↗

Phase 1 Completed 82 enrolled Bial - Portela C S.A.
RandomizedParallel-groupDouble-blindTreatment

Summary

To investigate the effect of repeated dosing of BIA 9-1067 on the levodopa pharmacokinetics, in comparison to placebo and entacapone.

Timeline

Start
2009-11
Primary completion
2010-02
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Entacapone Small molecule 200 mg —
Subject Levodopa Unknown 100 mg —
Subject Opicapone Small molecule 5 mg —
Subject Opicapone Small molecule 15 mg —
Subject Opicapone Small molecule 30 mg —
Background Carbidopa Unknown 25 mg —

Indications